Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off; and ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways. The companyís principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma multiforme. In addition, the company has ZFP therapeutic pre-clinical stage programs in the areas of Parkinsonís disease and hemophilia B. Further, it has ZFP therapeutic research programs in the areas of monogenic diseases, which include hemophilia A; hemoglobinopathies, such as sickle cell anemia and beta-thalassemia; lysosomal storage diseases; and immune system disorders comprising X-linked severe combined immunodeficiency. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Pfizer Inc.; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.